Pan-Salmonella-with-Alum vaccine

**Pan-Salmonella-with-Alum vaccine** is an investigational, alum-adjuvanted quadrivalent vaccine from GSK Vaccines Institute for Global Health designed to prevent invasive disease caused by *Salmonella enterica* serovars Typhi, Paratyphi A, Typhimurium, and Enteritidis. The formulation combines a commercial typhoid conjugate vaccine component, an O:2-CRM197 glycoconjugate component for *S. Paratyphi* A, and GMMA components presenting O-antigens from *S.* Typhimurium and *S.* Enteritidis; alum is included to enhance vaccine immunogenicity. ([sanctr.samrc.ac.za](https://sanctr.samrc.ac.za/TrialDisplay.aspx?TrialID=14967))\n\nThe candidate is being evaluated in the randomized, controlled, observer-blind Phase 1 study NCT07663032/GSK study 300281 in healthy adults aged 18 to 45 years in Africa, with safety, reactogenicity, and immune responses as primary development objectives. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663032))

Other names

GVGH Quadrivalent Pan-Salmonella Vaccine With AlumPan-Salmonella vaccine with AlumPan-Salmonella-with-Alum vaccine